Skip to main content

Day: May 6, 2021

Identity Theft Protection Services Market to Register 13.7% CAGR till 2028; Increasing Usage of Internet-based Financial Transactions to Augment Market Growth: Fortune Business Insights™

List of the Companies Profiled in the Market: Equifax Inc,LexisNexis Risk Solutions,AllClear ID,Experian Information Solutions Inc,Fair Isaac Corporation,NortonLifeLock Inc,TransUnion LLC,IdentityForce Inc,IdentityIQ,LifeLock, Inc. (Symantec),Identity Guard,Privacy Guard (Trilegiant Corporation), ADT,Threat Mark,My Digita lProtection,Cyberscout LLC,Kroll Pune, India, May 06, 2021 (GLOBE NEWSWIRE) — The global identity theft protection services market size is projected to reach USD 24.90 billion by 2028, exhibiting a CAGR of 13.7% during the forecast period. Fortune Business Insights™ shares this information in its report, titled “Identity Theft Protection Services Market, 2021-2028”. As per the report, the value of the market stood at USD 8.94 billion in 2020. Market Segmentation We have categorized the market on the basis of type,...

Continue reading

Auction of Treasury Bills on 10 May 2021

The treasury bills for sale have the following stock exchange codes:        Name Stock exchange code MaturityDGTB 01/09/21 21 / III 98-18262 1 September 2021DGTB 01/12/21 21 /  IV 98-18346 1 December 2021DGTB 01/03/22 22 / I 98-18429 1 March 2022The sale will settle on 12 May 2021 at the stop-rate for each serie. In case of bid on stop-rate a pro-rata ratio may occur. The deadline for bidding is 10.15 on the day of the auction.

Continue reading

Spar Nord investigates the potential for issuing Senior Non-Preferred (MREL capital)

Company announcement no. 14 As an element in complying with the capital demands that follow from the bank’s appointment as Systemically Important Financial Institution, Spar Nord has decided to investigate the potential for issuing new Senior Non-Preferred (so-called MREL capital). In this connection, Spar Nord has mandated Danske Bank, SEB and Nordea as Joint Lead Managers to arrange a series of virtual investor meetings and subsequently explore market interest for the potential issue. Subject to market conditions and investor feedback, Senior Non-Preferred issuance in SEK and/or NOK with intermediate tenor will follow. The issue will be documented with Spar Nord’s EMTN program, and the bonds will be listed on Euronext in Dublin. The bonds are expected to receive a rating from Moody’s of A3. Please direct any questions regarding...

Continue reading

Gilde Healthcare Acquires Majority Stake in Danish Drug Development Consultancy KLIFO to Support International Growth Ambitions

Northern European integrated drug development consultancy aims to further expand service offering and geographical footprint UTRECHT, the Netherlands and COPENHAGEN, Denmark, May 06, 2021 (GLOBE NEWSWIRE) — Gilde Healthcare, a specialized healthcare investor, and KLIFO A/S, a leading Northern European drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects, today announce that Gilde Healthcare’s Private Equity fund has acquired a majority stake in KLIFO. Gilde Healthcare aims to support KLIFO’s growth in the dynamically developing pharma outsourcing sector. KLIFO is the largest drug development consultancy in Denmark, with growing operations in Northern Europe. Headquartered in Copenhagen in Medicon Valley, one of Europe’s largest...

Continue reading

Dassault Systèmes: declaration of the number of outstanding shares and voting rights as of April 30, 2021

Declaration of the number of outstanding shares and voting rights as of April 30, 2021 Vélizy-Villacoublay (France) May 6, 2021 – Dassault Systèmes (Euronext Paris: #13065, DSY.PA) reports below the total number of its outstanding shares and voting rights as of April 30, 2021, according to articles 223-16 and 221-3 of the General Regulation of the Autorité des marchés financiers.         Number of outstanding shares: 265,574,581          Number of voting rights*: 397,355,458 *The total number of voting rights is calculated on the basis of the total number of outstanding shares, even if the voting rights attached thereto are suspended, pursuant to Article 223-11 of the General Regulation of the Autorité des marchés financiers relating to the method for calculating the percentages of holdings in shares and in voting rights. We invite our...

Continue reading

RGIS STRENGTHENS ITS GROWTH STRATEGY WITH THE ACQUISITION OF IVALIS GROUP

               RGIS STRENGTHENS ITS GROWTH STRATEGY WITH THE ACQUISITION OF IVALIS GROUP       Malakoff, May 5th2021 RGIS Inventory Specialists, market leader in Inventory and Retail Services, announces the acquisition of the control of Ivalis. Ivalis specialized in Inventory and Retail Services in many European countries (France, Germany, Austria, Switzerland, Spain, Portugal, Belgium, Holland, Italy) and also Brazil. This friendly takeover took place on 30 April 2021 and was paid fully in cash and fully funded by RGIS Group. “RGIS and Ivalis were competitors for many years and have both always maintained a strong common ethical value with respect for both employees and customers. Our people are our strength and we will need the combined talent of both RGIS and Ivalis, to continue to deliver our high level of service...

Continue reading

Core One Labs Commences Development on Patent Pending Psychedelic Drug Formulation for the Treatment of Alzheimer’s Disease

VANCOUVER, British Columbia, May 06, 2021 (GLOBE NEWSWIRE) — Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or “Core One”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the development of its next-generation patent pending psychedelic drug formulation for the treatment of Alzheimer’s Disease (“Alzheimer’s”). Akome’s ‘next-generation’ psychedelic drug formulation, also known as AKO002, is comprised of the psychedelic compound psilocybin and a plant bioactive which, when combined together, are believed to be complementary and/or synergistic in the treatment of Alzheimer’s. A provisional matter of composition patent application for AKO002 has been filed with the United States Patent and Trademark Office (USPTO) under application number...

Continue reading

Acquisition of ISS A/S shares by Group CFO

Company Announcement Copenhagen, 6 May 2021 No. 15/2021 Acquisition of ISS A/S shares by Group CFO ISS A/S (ISS.CO, ISS DC, ISSDY), a leading workplace experience and facility management company, has received notification pursuant to article 19 of the Market Abuse Regulation of transactions in ISS A/S’ shares made by persons discharging managerial responsibilities in ISS A/S and/or their closely associated persons. Group CFO Kasper Fangel has purchased 1,557 shares in ISS A/S (as described in attached notification) and now holds a total of 4,192 shares in the company. For investor enquiries Michael Bjergby, Head of Group Investor Relations, +45 31 37 41 71 Louisa Baruch Larsson, Senior Investor Relations Manager, +45 38 17 63 38 For media enquiries Kenni Leth, Head of Global PR & Media Relations, +45 51 71 43 68 About ISS ISS is...

Continue reading

TDC: Interim Financial Report Q1 2021

Improved or stable commercial performance across all main products in TDC Group as well as continued cost savings resulted in a small decline in EBITDA in Q1 (-1.8% YoY) TDC Group’s operating expenses improved by 11.5% YoY in Q1, driven by cost reductions across TDC Group, primarily in Nuuday (13.7%) Capex decreased by 27.6% YoY, driven by reduced costs following the completion of last year’s mobile network 5G-swap as well as lower activity in fibre rollout due to COVID-19 Leverage for DKT Finance was 5.3x (5.3x in Dec 2020) and for TDC A/S 3.6x (3.5x in Dec 2020). Additional RCF of DKK 2.577m was raised in Q1 to secure sufficient liquidity to cash flows the next 24 months – including operations, investment programs and maturing funding in 2022 TDC NET’s EBITDA totaled DKK 1,154m, increasing by 72m from Q4 2020 to Q1, however a decrease...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.